A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth

Overview

This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).

This study will enroll infants with potential tanezumab exposure in utero at sites overseen by Schulman and Associates IRB This study will attempt to enroll all infants who qualify.

Conditions

Interventions

Eligibility

Locations (8)

Outcomes